2019 Our goal of characterizing potential Alzheimer therapeutics is based on our success in identifying compounds from the original screening of drugs previously approved by the U.S. Food and Drug Administration for the treatment of other diseases. We will study the changes in pathological proteins that are affected by candidate Alzheimerās ...
December 20, 2018
The immune system uses complement proteins and receptors to ācoat and clearā pathogens and proteins from the body. Complement Receptor 1 (CR1/CD35) is found on the surface of red blood cells in humans and helps shuttle cellular debris to the liver for degradation. Recently, specific genetic variations, called polymorphisms, in ...
December 6, 2012
In a paper published in Molecular Neurodegeneration, Dr. Charles Glabe, a member of the Cure Alzheimerās Fund Research Leadership Group, reports that treatment with the drug PLX3397 decreased the overall number of amyloid plaques in the brain and also altered the process of plaque formation. Importantly, treatment with this drug ...
October 25, 2018
Margaret (Peggie) Royena Miller JohnsonApril 28, 1923 – March 22, 2016 Life-long Daytona Beach resident, Margaret (Peggie) Royena Miller Johnson passed from this life on March 22, 2016. Ninety-three years ago this week, she arrived into the world in the house her father built by hand at 215 South Wild Olive ...
April 28, 2016
Cure Alzheimerās Fund has, as a founding principle, a commitment to funding innovative research ideas that may not meet the criteria for funding from the National Institute of Health. Curing Alzheimerās disease will require audacious ideas that tackle disease mechanisms by leaving no stone unturned. A recent article in STAT ...
December 13, 2018
The loss of memory at advanced age that is typical of Alzheimerās disease begins silently and progresses steadily over a long period of time. During this time, protein clumps (amyloid plaques and neurofibrillary tangles) build up in the brain. The currently available drugs can only modestly slow down the failing ...
December 18, 2018
Neuroinflammation is a pathological hallmark of Alzheimerās disease. In Alzheimerās patients, the number of neutrophils is increased on the walls of the blood vessels. Neutrophils are a type of white blood cell that protect the human body from infections. In an Alzheimerās mouse model, neutrophils are found near amyloid plaques. ...
January 11, 2022
2019 The microglial regulator CD33 controls brain amyloid beta clearance in Alzheimerās disease. Through an unbiased high-throughput screen, we identified medications that increased amyloid beta uptake and maintained microglia in an anti-inflammatory activation state. CD33-specific antibodies that dramatically reduced CD33 levels also were identified. This project will investigate the mechanism of ...
December 20, 2018
On Alan Arnetteās 58thĀ birthday, July 27, he and his team reached the summit of K2 in Pakistanāone of the most challenging mountains in the world. K2 is his latest feat in a tireless effort to raise awareness of and money for Alzheimerās.Ā Having climbed dozens of mountains, including Everest, Alan has ...
May 15, 2014
Please join us for 6thĀ annual research symposium, featuring an update on Alzheimer’s research fromĀ Murali Doraiswamy, M.D.,Ā Beth Stevens, Ph.D., andĀ Rudy Tanzi, Ph.D. Schedule 2:00 p.m. Film Screening Rabb Hall Living With Alzheimerās Film Competition – 2015 Winning Entries Four short films plus discussion withĀ David Shenk, author ofĀ The Forgetting,Ā andĀ Eric Latek, Grand Prize-winning filmmaker 4:00 p.m.Ā RESEARCH SYMPOSIUM Rabb Hall WELCOME: Henry McCance ...
July 11, 2016
